KCM
CNST

Kennedy Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Kennedy Capital Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-89,891
Closed -$2.1M – 698
2021
Q1 		$2.1M Buy
+89,891
New +$2.72M 0.04% 510

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kennedy Capital Management's CNST Position: Q2 2021 in Review

Kennedy Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 89,891 shares — an estimated $2.1M sold.

Kennedy Capital Management first reported a position in CNST in Q1 2021 and held it in 1 quarter. The position peaked at $2.1M in Q1 2021. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Kennedy Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Kennedy Capital Management sold 89,891 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $2.1M.
  • Kennedy Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Kennedy Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $2.1M in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Kennedy Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.